• 1
    Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 4: 842845.
  • 2
    Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 5: 11831192.
  • 3
    Lalor P, Faint J, Aarbodem Y, Hubscher S, Adams D. The role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis 2007; 2: 173193.
  • 4
    Hillgartner FB, Salati LM, Goodridge AG. Physiological and molecular mechanisms involved in nutritional regulation of fatty acid synthesis. Physiol Rev 1995; 1: 4776.
  • 5
    Nohturfft A, DeBose-Boyd RA, Scheek S, Goldstein JL, Brown MS. Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc Natl Acad Sci U S A 1999; 20: 1123511240.
  • 6
    Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005; 5: 13331342.
  • 7
    Schmitz G, Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim Biophys Acta 2005; 1: 119.
  • 8
    Francavilla A, Carr BI, Azzarone A, Polimeno L, Wang ZQ, Vanthiel DH, et al. Hepatocyte proliferation and gene-expression induced by triiodothyronine in-vivo and in-vitro. HEPATOLOGY 1994; 5: 12371241.
  • 9
    Ruan XZ, Varghese Z, Fernando R, Moorhead JF. Cytokine regulation of low-density lipoprotein receptor gene transcription in human mesangial cells. Nephrol Dial Transplant 1998; 6: 13911397.
  • 10
    Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 6: H2721H2728.
  • 11
    Gamble W, Vaughan M, Kruth HS, Avigan J. Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res 1978; 8: 10681070.
  • 12
    Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation. Kidney Int 2001; 5: 17161725.
  • 13
    Ruan XZ, Moorhead JF, Tao JL, Ma KL, Wheeler DC, Powis SH, et al. Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines. Arterioscler Thromb Vasc Biol 2006; 5: 11501155.
  • 14
    Sung KC, Ryan MC, Kim BS, Cho YK, Kim BI, Reaven GM. Relationships between estimates of adiposity, insulin resistance and nonalcoholic fatty liver disease in a large group of nondiabetic korean adults. Diabetes Care 2007; 8: 21132118.
  • 15
    Canbay A, Bechmann LP, Best J, Jochum C, Treichel U, Gerken G. Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z Gastroenterol 2006; 3: 245248.
  • 16
    Bleibel W, Thukral C, Robson SC. Overlap between systemic lupus erthematosus and nonalcoholic steatohepatisis: response. J Clin Gastroenterol 2006; 6: 561562.
  • 17
    Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Z Gastroenterol 2007; 1: 6370.
  • 18
    Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diabetes Rep 2002; 3: 210215.